Telehealth platforms that still offer compounded GLP-1s narrow to a patient-specific pathway
New ratings from U.S. News and a separate Forbes Health list show most major GLP-1 telehealth platforms now emphasize FDA-approved brand-name drugs, while compounded versions persist at a smaller number of providers.
U.S. News & World Report published its first-ever ratings of telehealth platforms that prescribe GLP-1 medications on August 12, evaluating 20 platforms that offer FDA-approved, brand-name drugs such as Wegovy, Zepbound, and Ozempic [1]. The ratings drew on 14,161 data points and feedback from more than 1,200 active GLP-1 users, and scored platforms across six categories: clinical support, screening rigor, transparency, insurance assistance, supplemental care, and overall customer satisfaction [1].
Of the 20 platforms reviewed, 11 received top ratings on a five-point scale. Amazon One Medical scored highest at 4.8, followed by Found at 4.6, Mochi Health and Ro tied at 4.4, Noom at 4.3, PlushCare at 4.1, Fridays, Ivim Health, and LifeMD each at 4.0, and Remedy Meds and WeightWatchers at 3.9 [1]. U.S. News also named category leaders: Amazon One Medical for insurance support, Found for clinical support, Noom for supplemental support, and Ro for customer satisfaction [1].
Importantly, U.S. News excluded companies that only offer compounded GLP-1s from its analysis entirely [1]. For platforms that offer both branded and compounded products, the publication says it evaluated only the branded side of their services [1], meaning the ratings do not directly assess how those companies handle compounded prescriptions.
A separate ranking from Forbes Health, last audited September 14, 2026, highlights some of that mixed landscape [2]. It names Mochi Health as the platform with "the most user-friendly website," noting the company offers both brand-name and compounded medications for eligible patients [2]. It also names Remedy Meds as the best option with no membership cost, describing it as a platform that "specializes in compounded medications, though they also offer Zepbound" [2]. Other Forbes Health picks — Ro, Hims & Hers, WeightWatchers Med+, and PlushCare — are described in terms of brand-name offerings [2].
The available reporting does not spell out which platforms restrict compounded prescriptions to the FDA's narrow patient-specific pathway, or detail any warning letters or lawsuits tied to specific companies. Those specifics are not established in the sources reviewed here, so readers should treat any list of compounding-focused platforms beyond Mochi Health and Remedy Meds as unconfirmed by this reporting.
Why it matters for patients
The shift toward brand-name products on major platforms reflects a market where FDA-approved supply has become more available, but it also means patients researching options need to check, platform by platform, whether compounded versions are still offered and under what conditions. U.S. News's decision to exclude compounded-only companies from its ratings means its list is not a complete picture of every telehealth option a patient might find [1].
Fatima Syed, a medical weight management specialist at Duke Health, said patients should be able to easily reach a medical professional and know who is available if they have questions, rather than feeling alone in their treatment [1]. Gretel Schueller of U.S. News added that patients should get real-time interaction with a clinician, not just asynchronous messaging, and that clinical oversight — including blood work checking kidney and liver function — matters because these are prescription medications with real risks for people with certain health histories [1].
A joint advisory from four medical organizations, including the Obesity Medicine Association and The Obesity Society, said patients prescribed GLP-1s through any channel should receive a thoughtful plan of care that includes nutritional and lifestyle counseling before, during, and after treatment [1].
What happens next
U.S. News released its ratings on August 12, 2026, and plans to continue evaluating the growing field of GLP-1 telehealth companies [1]. Forbes Health's separate list was last audited on September 14, 2026, indicating ongoing tracking of which platforms offer branded versus compounded products [2]. No further dated milestones for regulatory action against specific compounding platforms are detailed in the sources reviewed.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.